hers glp 1 commercial Super Bowl ad for Hims & Hers' weight loss drug sparks backlash Health care exec shares her

Conversely, emerging opportunities support future translation

Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits

Endocrinology 2014 , 155 , 12801290

The STEP-1 body-composition substudy (n=140 DXA cohort) of semaglutide (Wegovy at 2.4 mg weekly) reported fat-free mass loss of approximately 6.9 kg over 68 weeks, accounting for approximately 45% of total weight loss based on the body-composition substudys own arithmetic and the Conte 2024 systematic review [6, 7]

According to background information from the researchers, about one in every eight COVID patients will go on to experience long COVID

Ozempic or Tirzepatide?, and this is where understanding the key differences and benefits of these treatment options helps patients make an informed decision together with their healthcare provider